09/ 712129

February 9, 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.: RE39,198

Issued: July 18, 2006

Inventor: Joseph T. Strupczewski; Grover C. Helsley; Yulin Chiang; Kenneth J. Bordeau; Edward J. Glamkowski

Title: HETEROARYLPIPERIDINES, PYRROLIDINES AND PIPERAZINES AND THEIR USE AS ANTIPSYCHOTICS AND ANALGESICS

Atty. Docket No.: P25,984 REI

CERTIFICATE OF MAILING

I hereby certify that this correspondence, together with any other document indicated as being enclosed, was deposited with the U.S. Post Office as first-class mail, postage prepaid, in an envelope addressed to: Office of Petitions, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on February 09, 2007 .

February 9, 2007
Date

Barbara G. Makariou

Office of Petitions
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Certificate

FEB 1 6 2007

of Correction

### Petition Under 37 C.F.R. § 1.322(b) for Issuance of A Corrected Patent

Sir:

The patent owner petitions the Commissioner for issuance of a corrected patent for U.S. Patent No. RE39,198 in lieu of the issuance of a Certificate of Correction to correct printing errors, all of which are the result of Patent Office mistakes.

FEB 2 0 2007.

Listing of Errors

In column 3, line 30, the semicolon should appear after the chemical structure and not
as a part of the structure so that the structure

"   " reads --   ; --.

In column 4, line 20, in the structure, subscript q should appear in place of subscript
n, so that the structure

" $—(CH_2)_n—$ ...   "

reads

-- $—(CH_2)_n—$ ... --.

In column 6, line 50, the semicolon should appear after the chemical structure and not
as a part of the structure so that the structure the structure

"   lower alkyleneyl ... $(Z_1)_p$;   "

Synnestvedt & Lechner llp

U.S. Pat. No. RE39,198
Issued July 18, 2006

February 9, 2007
S&L File No. P25,984 REI

Page 3

reads --   lower alkyleneyl—[structure with $(Z_1)_p$] ;   --.

In column 7, line 25, the semicolon should appear after the chemical structure and not as a part of the structure so that the structure

" —[structure with R_5;] " reads -- —[structure with R_5] ; --.

In column 9, line 29, the term "R 19" should read -- R_{19} --.

In column 9, line 49, the term "R 12" should read -- R_{12} --.

In column 11, line 65, the term "where" should read -- when --.

In column 11, line 66, a space should appear in the term "C_1–C_4alkoxy" so that the term reads -- C_1–C_4 alkoxy --.

In column 15, line 60, the semicolon should appear after the chemical structure and not as a part of the structure so that the structure

" lower alkyleneyl—[structure with $(Z_1)_p$;] "

reads

-- lower alkyleneyl—⬡$(Z_1)_p$;   --.

In column 16, line 40, the semicolon should appear after the chemical structure and

not as a part of the structure so that the structure

" —⬡R_5; " reads --   —⬡R_5 ;   --.

In column 20, line 56, the term "where" should read -- when --.

In column 24, lines 20 to 21, the structure fragment

"—CH$_2$—CH=C—H—CH$_2$— " should read

-- —CH$_2$—CH=CH—CH$_2$— --.

In column 28, line 47, the term "as font" should read -- an inert --.

In column 28, line 64, the term "cuprons" should read -- cuprous --.

In column 28, line 64, the term "solved" should read -- solvent --.

In column 28, line 65, the term "tetramethylures" should read -- tetramethylurea --.

In column 28, line 66, a space should appear in the term "1to", so that the term reads

-- 1 to --.

In column 29, line 18, the term "ClCN," should read -- ClCN --.

In column 29, line 19, the term "a" should read -- or --.

In column 29, line 35, the term "(5)" should read -- (15) --.

In column 29, line 40, a space should appear in the term "6to" so that the term reads
        -- 6 to --.

In column 29, line 52, the term "much" should read -- such --.

In column 29, line 52, the term "as sodium" should read -- e.g., sodium --.

In column 29, line 54, the term "at" should read -- a --.

In column 29, line 55, a colon should appear in place of the semicolon in the term
        "(17);" so that the term reads -- (17): --.

In column 29, line 65, the term "as" should read -- out --.

In column 30, line 66, the term "J." should read -- in J. --.

In column 31, line 25, the term "piperidines" should read
        -- indazole-substituted piperidines --.

In column 31, line 26, the term "are" should be deleted.

FEB 2 0 2007

In column 31, line 27, the term "i" should read -- in --.

In column 32, line 6, the term "Section" should read -- Sections--.

In column 32, line 19, the term "as" should read -- can --.

In column 32, line 20, the term "Is" should read -- In --.

In column 32, line 31, a space should appear in the term "7to", so that the term reads
        -- 7 to --.

In column 32, line 32, the term "is" should read -- in --.

In column 32, line 40, the phrase "such a" should read -- such as --.

In column 32, line 43, a space should appear in the term "4to", so that the term reads
        -- 4 to --.

In column 32, line 45, the term "be Isolated" should read -- be isolated --.

In column 32, line 54, the fragment "piperanzinyl" should read -- piperazinyl --.

In column 32, line 58, the fragment "piperanzinyl" should read -- piperidinyl --

In column 32, line 61, a hyphen should appear in the fragment "3methoxyphenyl" so
        that the fragment reads -- 3-methoxphenyl --.

In column 32, line 66, the fragment "piperanzinyl" should read -- piperazinyl --.

In column 33, line 1, the fragment "[4-[2-[4-" should read --1-[4-[2-[4- --.

In column 33, line 1, the fragment "piperandinyl" should read -- piperidinyl --.

In column 33, line 3, the fragment "[3-[4-" should read -- 4-[3-[4- --.

In column 33, line 3, the fragment "piperandinyl" should read -- piperidinyl --.

In column 33, line 5, the fragment "[4-[3-[4-" should read --1-[4-[3-[4- --.

In column 33, line 7, the fragment "[4-[3-[4-" should read -- 1-[4-[3-[4- --.

In column 33, line 7, the fragment "piperandinyl" should read -- piperidinyl --.

In column 33, line 8, the fragment "hydrozyphenyl" should read -- hydroxyphenyl --.

In column 33, line 9, the fragment "[4-[3-[4-" should read --1-[4-[3-[4- --.

In column 33, line 9, the fragment "piperandinyl" should read --piperazinyl --.

In column 33, line 11, the fragment "[4-[4-[4-" should read --1-[4-[4-[4- --.

In column 33, line 11, the fragment "piperandinyl" should read --piperazinyl --.

In column 33, line 13, the fragment "piperanzinyl" should read -- piperidinyl --.

FEB 2 0 2007

In column 33, line 14, a hyphen should appear in the fragment "3methoxyphenyl" so
that the fragment reads -- 3-methoxyphenyl --.

In column 33, line 16, the fragment "piperandinyl" should read -- piperidinyl --.

In column 33, line 18, the fragment "piperandinyl" should read -- piperidinyl --.

In column 33, line 20, the fragment "piperandinyl" should read -- piperidinyl --.

In column 33, line 22, a hyphen should appear in the fragment "6fluoro" so that the
fragment reads -- 6-fluoro --.

In column 33, line 23, the fragment "piperandinyl" should read -- piperidinyl --.

In column 33, line 24, the fragment "piperandinyl" should read -- piperidinyl --.

In column 33, line 26, the fragment "piperanzinyl" should read -- piperidinyl --.

In column 33, line 29, the fragment "piperandinyl" should read -- piperidinyl --.

In column 33, line 30, the fragment "piperandinyl" should read -- piperidinyl --.

In column 33, line 32, the fragment "piperandinyl" should read -- piperidinyl --.

In column 33, line 34, the fragment "piperandinyl" should read -- piperidinyl --.

In column 33, line 53, the fragment "6-benzoyl" should read -- 1-benzoyl --.

In column 33, line 61, no hyphen should appear in the fragment

"piperidinyl]-proproxy" so that the fragment reads -- piperidinyl]proproxy --.

In column 34, line 40, a hyphen should appear in the fragment

"-3methoxyphenoxy)" so that reads -- -3-methoxyphenoxy) --.

In column 34, line 50, the fragment "benzisoxazol" should read -- benzisothiazol --.

In column 34, line 51, a hyphen should appear in the fragment "-3methoxyphenoxyl"

so that the fragment reads -- -3-methylaminophenyl --.

In column 34, line 52, the fragment "benzisoxazol" should read -- benzisothiazol --.

In column 34, line 53, a hyphen should appear in the fragment "-4methoxyphenyl" so

that the fragment reads -- -4-methoxyphenyl --.

In column 34, line 54, the fragment "benzisoxazol" should read -- benzisothiazol --.

In column 34, line 55, a hyphen should appear in the fragment "-3methoxyphenyl" so

that the fragment reads -- -3-methoxyphenyl --.

In column 35, line 13, a hyphen should appear in place of zero in the fragment "01,"

so that the fragment reads -- -1, --.

In column 35, line 14, the closed bracket character in the fragment "hydroxypropyl]"

should be a closed parenthesis character, so that the fragment reads

-- hydroxypropyl) --.

In column 35, line 30, the fragment "propyl-" should read -- propyl]- --.

In column 35, line 35, the fragment "(4(6" should read -- (4-(6 --.

In column 35, line 45, the fragment "methoxypheyl" should read

-- methoxyphenyl --.

In column 35, line 48, the fragment "(1,2-dithian" should read --(1,3-dithian --.

In column 36, line 12, no hyphen should appear in the fragment "methoxyphenyl-]" so

that the fragment reads -- methoxyphenyl] --.

In column 36, line 41, a hyphen should appear in the fragment "oxy]3-" so that the

fragment reads -- oxy]-3- --.

In column 36, line 52, the fragment "(,2" should read -- (1,2 --.

In column 36, line 52, the fragment "piperidinyl" should read -- piperazinyl --.

In column 36, line 53, a letter el should appear in place of the first closed bracket

symbol in the fragment "methoxy]butoxy]" so that the fragment reads

-- methylbutoxy]--.

In column 36, line 60, the term "a" should read -- an --.

SYNNESTVEDT & LECHNER LLP
U.S. Pat. No. RE39,198
Issued July 18, 2006

February 9, 2007
S&L File No. P25,984 REI
Page 11

In column 37, line 29, a space should appear in the term "3readings" so that the term reads -- 3 readings --.

In column 38, line 26, the term "so" should read -- to --.

In column 38, line 29, the term "1937" should read -- 1957 --.

In column 38, line 53, the term "dosage" should read -- specific dosage --.

In column 38, line 57, the term "damages" should read -- dosages --.

In column 39, line 4, the duplicate phrase "include salts" should be deleted.

In column 39, line 17, the phrase "troches, gums," should read -- troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums, --.

In column 39, line 31, the term "primogel" should read --Primogel --.

In column 39, line 32, the first term "glidant" should read --lubricant --.

In column 39, line 34, the term "of" should read -- or --.

In column 39, line 34, the term "an" should read -- as --.

In column 39, line 42, a comma should appear after the term "contain" so that the term reads -- contain, --.

In column 39, line 44, the term "used" should read -- used in --.

In column 39, line 46, an "s" should appear in place of a comma, so that the term
       "amount," reads -- amounts --.

In column 39, line 50, the term "0.1% a" should read -- 0.1% of a --.

In column 39, line 56, a space should appear in the term "05to" so that the term reads
       -- 05 to --.

In column 39, line 60, the term "agents" should read -- antibacterial agents --.

In column 39, line 63, the term "at" should read -- as --.

In column 40, line 10, the fragment "3-bromobenzoic" should read
       -- 2-bromobenzoic --.

In column 40, line 15, the phrase "7.3 ml" should read -- 78.3 ml --.

In column 40, line 26, the phrase "(125 g, (1.35 mol)" should read
       -- (125 g, 0.35 mol) --.

In column 40, line 27, a space should appear in the term "2hours" so that the term
       reads --2 hours-- .

In column 40, line 33, the fragment "hydroaono" should read -- hydrazono --.

column 40, line 49, the fragment "(2-bromophenyrmethyl" should read -- (2-bromophenyl)methyl --.

In column 40, line 52, the fragment "1-indazole" should read -- 1H-indazole --.

In column 40, line 53, the term "hydrazone" should read -- hydrazono --.

In column 41, line 2, a period should appear in the abbreviation in place of a comma in the term "m.p,=" so that the abbreviation reads -- m.p.= --.

In column 41, line 5, the fragment "C_1" should read -- C_{18} --.

In column 41, line 16, the term "25 ml" should read -- 525 ml --.

In column 41, line 24, the fragment "C_1" should read -- C_{18} --.

In column 41, line 32, a space and the letter "l" (el) should appear in place of the numeral "1" (one), so that the term "(2.01)" reads -- (2.0 1) --.

In column 41, line 38, the term "war" should read -- was --.

In column 41, line 58, the term "7.3" should read -- 7.5 --.

In column 41, line 64, the term "(50 ml) should read -- (150 ml) --.

In column 42, line 8, the fragment "N4" should read -- N_4 --.

FEB 2 0 2007

In column 42, line 10, the fragment "4-1H" should read -- 4-(1H --.

In column 42, line 12, the term "(.3 g," should read -- (5.3 g, --.

In column 42, line 14, the fragment "3-(-4-methyl]-piperazinyl)" should read
    -- 3-(4-methyl-1-piperazinyl) --.

In column 42, line 15, the term "(60)" should read -- (60 ml) --.

In column 42, line 28, a closed parenthesis symbol should appear in the fragment
    "Piperazinyl-1" so that the fragment reads -- Piperazinyl)-1--.

In column 42, line 29, the numeral four should not be bold and a hyphen should appear
    after the numeral in the fragment "4 (1H" so that the fragment reads
    -- 4-(1H --.

In column 42, line 38, the number "158" should read -- 155 --.

In column 42, line 41, the number "27.70%" should read -- 27.80% --.

In column 42, line 42, a hyphen should appear in the fragment "[4(1H" so that the
    fragment reads -- [4-(1H --.

In column 42, line 47, the fragment "methoxypbenyl]" should read
    -- methoxyphenyl] --.

FEB 2 0 2007

In column 42, line 55, the fragment "(4-(1H-" should read -- [4-(1H- --.

In column 42, line 56, a closed bracket symbol should appear in place of a space in the

   fragment "piperazinyl propoxy" so that the fragment reads

   -- piperazinyl]propoxy --.

In column 42, line 63, the fragment "piperadinyl" should read -- piperidinyl --.

In column 43, line 8, the term "eluent" should read -- as eluent --.

In column 43, line 13, the term "102°101°" should read -- 102°–104° --.

In column 43, line 21, the fragment "piperadinyl" should read -- piperidinyl --.

In column 43, line 25, the phrase "0.04 g, mol" should read -- 0.04 mol --.

In column 43, line 25, an open bracket symbol should appear in place of the first open

   parenthesis symbol, and a closed parenthesis symbol should appear in the

   fragment "1-(4-(3-chloropropoxy-3-" so that the fragment reads

   -- 1-[4-(3-chloropropoxy)-3- --.

In column 43, line 27, the term "hour" should read -- hours --.

In column 43, line 33, a hyphen should appear in the term "-3methoxyphenyl" so that

   the fragment reads -- -3-methoxyphenyl --.

In column 43, line 53, a hyphen should appear in the fragment "butoxy]3-" so that the

fragment reads -- butoxy]-3- --.

In column 43, line 63, an closed bracket symbol should appear in place of the closed parenthesis symbol in the fragment "piperidinyl)" so that the fragment reads -- piperidinyl] --.

In column 43, line 63, the fragment "methoxyohenylethanone" should read -- methoxyphenylethanone --.

In column 44, line 22, the fragment "Benzisoxazole" should read -- Benzisoxazol --.

In column 44, line 24, an extra hyphen should not appear the fragment "3-(-4-" so that the fragment reads -- 3-(4- --.

In column 44, line 25, the term "hydride" should read -- hydrochloride --.

In column 44, line 30, the term ($MgSO_3$) should read -- ($MgSO_4$) --.

In column 44, line 33, the term "3.9" should read -- 5.9--.

In column 44, line 34, the term "is" should read -- in --.

In column 44, line 35, a numeral one and a comma in place of a period should appear in the phrase "(.2 g. 1.1 equiv.)" so that the phrase reads -- (1.2 g, 1.1 equiv.) --.

In column 44, line 37, a space should appear in the term "2hours" so that the term

SYNNESTVEDT & LECHNER LLP
U.S. Pat. No. RE39,198
Issued July 18, 2006

February 9, 2007
S&L File No. P25,984 REI
Page 17

reads -- 2 hours --.

In column 44, line 38, the term "solutions" should read -- solution --.

In column 44, line 45, a centerdot should appear between fragments "$C_{23}H_{26}N_2O_4$" and "$C_4H_4O_4$" so that the fragments read -- $C_{23}H_{26}N_2O_4 \cdot C_4H_4O_4$ --.

In column 44, line 50, the fragment "piperizinyl" should read -- piperazinyl --.

In column 44, line 54, a comma should appear in place of a period in the term "mol)." so that the term reads -- mol), --.

In column 44, line 55, a hyphen should appear in the fragment "3methoxyphenyl" so that the fragment reads -- 3-methoxyphenyl --.

In column 44, line 56, a space should appear in the term "6hours" so that the term reads --6 hours --.

In column 44, line 65, the fragment "piperizinyl]butoxy)" should read -- piperazinyl]butoxy] --.

In column 45, line 10, the term "(5.2)" should read -- (5.2 g) --.

In column 45, line 11, the fragment "methoxypbenyl" should read -- methoxyphenyl --.

In column 45, line 13, the term "C. For" should read -- C. for --.

FEB 2 0 2007

In column 45, line 36, the second term "-3-yl)" should be deleted.

In column 45, line 42, a space should appear in the term "3hours" so that the term

reads --3 hours --.

In column 45, line 46, a period should appear after the term "material" so that the term

reads -- material. --.

In column 45, line 63, a comma should appear in place of a period in the term "3.0 g."

so that the term reads -- 3.0 g, --.

In column 46, line 6, the phrase "upon solidified on standing." should read

-- which solidified upon standing. --

In column 46, line 7, the term "42 g" should read -- 4.2 g --.

In column 46, line 11, a hyphen should appear in place of a space in the fragment

"2 benzisothiazol" so that the fragment reads -- 2-benzisothiazol --.

In column 46, line 12, the term "96°" should read -- 95° --.

In column 46, line 16, the term "6.39%" should read -- 6.59% --.

In column 46, line 21, the fragment "piperdinynl" should read -- piperidinyl --.

In column 46, line 23, the fragment "[4-(3-hydroxyphenyl]" should read

-- [4-(3-chloropropoxy)-3-hydroxyphenyl] --.

In column 46, line 29, the term "compete" should read -- complete --.

In column 46, line 38, the term "an" should read -- on --.

In column 46, line 38, the term "Prop" should read -- Prep--.

In column 46, line 38, a space should appear in the term "2silica" so that reads
        -- 2 silica --.

In column 46, line 41, the term "factions" should read -- fractions --.

In column 46, line 43, the term "other" should read -- ether --.

In column 46, line 44, the term "off" should read -- of --.

In column 46, line 45, the term "as" should read -- an --.

In column 46, line 49, a hyphen should appear in the fragment "3hydroxyphenyl" so
        that the fragment reads -- 3-hydroxyphenyl --.

In column 46, line 52, a space should appear in the term "2.8g," so that the term reads
        -- 2.8 g, --.

In column 46, line 52, a comma should appear after the term "mol)" so that the term
        reads -- mol), --.

SYNNESTVEDT & LECHNER LLP
U.S. Pat. No. RE39,198
Issued July 18, 2006

February 9, 2007
S&L File No. P25,984 REI
Page 20

In column 46, line 53, the term "crystal" should read -- crystals --.

In column 46, line 65, the fragment "benzisoxazole" should read -- benzisoxazol --.

In column 46, line 66, the term "Yellow" should read -- yellow --.

In column 47, line 12, a period should appear in place of a comma in the term "0,011"
so that the term reads -- 0.011--.

In column 47, line 13, a space should appear in the term "(60ml)" so that the term
reads -- (60 ml) --.

In column 47, line 25, a closed bracket symbol should appear in place of a closed
parenthesis symbol in the fragment "methoxyphenyl)" so that the fragment
reads -- methoxyphenyl] --.

In column 47, line 34, the term "indazol-1" should read -- indazol-3-yl)-1 --.

In column 47, line 40, a space should appear in the term "(80ml)" so that the term
reads -- (80 ml) --.

In column 47, line 41, the term "73°" should read -- 75° --.

In column 47, line 41, a space should appear in the term "6hours" so that the term
reads -- 6 hours --.

Synnestvedt & Lechner llp

U.S. Pat. No. RE39,198
Issued July 18, 2006

February 9, 2007
S&L File No. P25,984 REI

Page 21

In column 47, line 41, a comma should appear in the phrase "water and" so that the phrase reads -- water, and --.

In column 47, line 44, a space should appear in the term "(3times)" so that the term reads -- (3 times) --.

In column 47, line 52, the term "138° C." should read -- 158 ° C. --.

In column 47, line 54, the phrase "63.44% C" should read -- 65.44% C --.

In column 47, line 54, the term "65.44% H" should read -- 6.64% H--.

In column 47, line 62, an extra hyphen should not appear in the term "(-4-" so that the term reads -- (4- --.

In column 47, line 63, the term "(1.6)," should read -- (1.6 g), --.

In column 47, line 63, an open bracket symbol should be in place of a closed bracket symbol in the term "1-]4" so that the term reads -- 1-[4 --.

In column 47, line 64, a comma should appear in the place of a semicolon in the term "5.3 g;" so that the term reads -- 5.3 g, --.

In column 48, line 4, no hyphen should appear in the phrase "chloride/-methanol" so that the phrase reads -- chloride/methanol --.

In column 48, line 6, a hyphen should appear in the fragment "1[4" so that the

fragment reads -- 1-[4 --.

In column 48, line 19, a closed parenthesis symbol should appear after the term "mol"
so that the term reads -- mol) --.

In column 48, line 19, the term "(2.8)" should read -- (2.8 g) --.

In column 48, line 28, the fragment "piperdinyl" should read -- piperidinyl --.

In column 48, line 41, the fragment "1-[4-[4(4-" should read -- 1-[4-(4- --.

In column 48, line 42, a hyphen should appear in the fragment "3methoxyphenyl" so
that the fragment reads -- 3-methoxyphenyl --.

In column 48, line 42, a space and a symbol "g" should appear in the term
"$K_2CO_3(2.8)$" so that the term reads -- K_2CO_3 (2.8 g) --.

In column 48, line 52, a comma should appear after the term "cooling" so that the term
reads -- cooling, --.

In column 48, line 58, a centerdot should appear in place of the colon in the formula
"$C_{25}H_{29}ClN_2O_4$:$C_4H_4O_4$" so that the formula reads -- $C_{25}H_{29}ClN_2O_4$·$C_4H_4O_4$ --.

In column 48, line 66, an extra hyphen should not appear in the fragment "(-4-" so that
the fragment reads -- (4- --.

In column 48, line 67, a hyphen should appear in the term "2benzisoxazole" so that the

SYNNESTVEDT & LECHNER LLP
U.S. Pat. No. RE39,198
Issued July 18, 2006

February 9, 2007
S&L File No. P25,984 REI
Page 23

fragment reads -- 2-benzisoxazole --.

In column 49, line 1, a space and a period should appear in the term "24g," so that the term reads -- 2.4 g, --.

In column 49, line 3, a space should appear in the term "8hours" so that the term reads -- 8 hours --.

In column 49, line 4, a space should not appear in the term "acetate ." so that the term reads -- acetate. --.

In column 49, line 5, a comma should appear after the term "($MgSO_4$)" so that the term reads -- ($MgSO_4$), --.

In column 49, line 15, a subscript "4" should appear in the formula "$C_{24}H_{27}FN_2O$:" so that the formula reads -- $C_{24}H_{27}FN_2O_4$: --.

In column 49, line 15, a period should appear in place of a comma in the term "67,59%" so that the term reads -- 67.59% --.

In column 49, line 17, the phrase "Found with):" should read -- Found: --.

In column 49, line 17, the phrase "6.53% H." should read -- 6.53% N. --.

In column 49, line 20, an extra hyphen should not appear in the fragment "(-2-methoxyphenoxy)" so that the fragment reads -- (2-methoxyphenoxy) --.

In column 49, line 22, an extra hyphen should not appear in the fragment
"(-4-piperidinyl)" so that the fragment reads -- (4-piperidinyl) --.

In column 49, line 23, the term "(2.0)" should read -- (2.0 g) --.

In column 49, line 24, the phrase "17.4 moles" should read -- 17.4 mmoles --.

In column 49, line 25, a space should appear in the term "(40ml)" so that the term
reads -- (40 ml) --.

In column 49, line 25, a space should appear in the term "4hr." so that the term reads
-- 4 hr. --.

In column 49, line 25, the term "and" should read -- end --.

In column 49, line 25, the term "advent" should read -- solvent --.

In column 49, line 29, the term "craft" should read -- crude --.

In column 49, line 37, the term "(3.68)" should read -- (3.68 g) --.

In column 49, line 38, a space should appear in the term "(13ml)." so that the term
reads -- (13 ml). --.

In column 49, line 39, a comma in place of a period and two hyphens should appear in
the fragment "4piperidinyl]1.2-benzisoxazole" so that the fragment reads
-- 4-piperidinyl]-1,2-benzisoxazole --.

SYNNESTVEDT & LECHNER LLP
U.S. Pat. No. RE39,198
Issued July 18, 2006

February 9, 2007
S&L File No. P25,984 REI
Page 25

In column 49, line 48, a hyphen should appear in the fragment "(-6-Fluoro" so that the fragment reads -- (6-Fluoro --.

In column 49, lines 51-52, a hyphen should appear in place of the space in the fragment "1,2 benzisoxazole" so that the fragment reads -- 1,2-benzisoxazole --.

In column 49, line 54, a space should appear in the term "(50ml)" so that the term reads -- (50 ml) --.

In column 49, line 55, the term "reflex" should read -- reflux --.

In column 49, line 55, a space should appear in the term "4hr." so that the term reads -- 4 hr. --.

In column 49, line 55, the term "and" should read -- end. --.

In column 49, line 64, the fragment "1-[4-[4-[4-(6-" should read -- 1-[3-[3-[4-(6- --.

In column 49, line 67, a closed parenthesis symbol should appear in the term "(63%," so that the term reads -- (63%), --.

In column 50, line 2, the formula "$C_{29}H_{29}FN_2O4$" should read -- $C_{29}H_{29}FN_2O_4$ --.

In column 50, line 8, a hyphen should appear in the fragment "[4(1H-indazol" so that the fragment reads -- [4-(1H-indazol --.

In column 50, line 10, a hyphen should appear in place of the space in the fragment "1H indazole" so that the fragment reads -- 1H-indazole --.

In column 50, line 12, a comma should appear after the term "0.016 mol)" so that the term reads -- 0.016 mol), --.

In column 50, line 12, the term "(2.2)" should read -- (2.2 g) --.

In column 50, line 13, a space should appear in the term "6hours." so that the term reads -- 6 hours. --.

In column 50, line 19, the fragment "piperidiyl" should read -- piperidinyl --.

In column 50, line 21, the formula "$C_{25}H_{31}N_3O3$:" should read -- $C_{25}H_{31}N_3O_3$: --.

In column 50, line 29, an additional hyphen should appear in the fragment "-3methoxyphenyl" so that the fragment reads -- -3-methoxyphenyl --.

In column 50, line 31, a comma should appear in place of a period, and another comma should appear after the phrase "(4.6 g. 0.019 mol)" so that the phrase reads -- (4.6 g, 0.019 mol), --.

In column 50, line 32, a comma should appear in place of a period in the phrase "(4.3 g." so that the phrase reads -- (4.3 g, --.

In column 50, line 32, the term "(2.8)" should read -- (2.8g) --.

In column 50, line 40, a comma should appear in place of the period in fragment "1.2" so that the fragment reads -- 1,2 --.

In column 50, line 45, the formula "$C_{23}H_{25}ClN_2O4$:" should read -- $C_{23}H_{25}ClN_2O_4$:--.

In column 50, line 48, the line should end with a period.

In column 50, line 54, a space should appear in the term "(35ml)" so that the term reads -- (35 ml) --.

In column 50, line 56, a space should appear in the term "5g" so that the term reads -- 5 g --.

In column 50, line 56, a closed parenthesis symbol should appear after the term "moles" so that the term reads -- moles) --.

In column 50, line 58, a space should appear in the term "2hr." so that the term reads -- 2 hr. --.

In column 50, line 64, a colon should appear the term "3.1" so that the term reads -- 3:1 --.

In column 50, line 65, the letter l should appear after the term "1.6" so that the term reads -- 1.6 l --.

In column 50, line 65, a space should appear in the term "1.41)." so that the term reads
-- 1.4 1). --.

In column 51, line 1, a space should appear in the fragment "4methoxyphenyl" so that
the fragment reads -- 4-methoxyphenyl --.

In column 51, line 4, the line should end with a period.

In column 51, line 11, the extra hyphen should not appear in the fragment
"-(-4-piperidinyl)" so that the fragment reads -- -(4-piperidinyl) --.

In column 51, line 11, a comma should appear in place of the period in the fragment
"1.2" so that the fragment reads -- 1,2 --.

In column 51, line 12, the phrase "4.53 in" should read -- 4.53 gm --.

In column 51, line 12, the phrase "20.5 moles" should read -- 20.5 mmoles --.

In column 51, line 13, the term "4.5 m" should read -- 4.5 gm --.

In column 51, line 13, a comma should appear in place of the period in the phrase
"6.4 g," so that the phrase reads -- 6.4 g. --.

In column 51, line 13 to 14, the phrase "29 moles" should read -- 29 mmoles --.

In column 51, line 14, a space should appear in the term "(60ml)" so that the term
reads -- (60 ml) --.

In column 51, line 14, a space should appear in the term "5hr." so that the term reads
-- 5 hr. --.

In column 51, line 19, a comma should appear in place of the period after the term
"SiO_2" so that the term reads -- SiO_2 --.

In column 51, line 26, a closed bracket symbol should appear in place of the closed
parenthesis symbol in the term "phenyl)" so that the term reads -- phenyl] --.

In column 51, line 29, two spaces should appear in the fragment "$O_4$63.27" so that the
fragment reads -- O_4 63.27 --.

In column 51, line 35, the extra hyphen should not appear in the fragment "3-[-4-(6-"
so that the fragment reads -- 3-[4-(6- --.

In column 51, line 36, the fragment "methyphenyl" should read -- methylphenyl --.

In column 51, line 37, the term "mature" should read -- mixture --.

In column 51, line 37, the extra hyphen should not appear in the fragment
"(-4-piperidinyl)" so that the fragment reads -- (4-piperidinyl) --.

In column 51, lines 37 to 38, a hyphen should appear in place of the space in the
fragment "1,2 benzisoxazole" so that the fragment reads
-- 1,2-benzisoxazole --.

Synnestvedt & Lechner llp
U.S. Pat. No. RE39,198
Issued July 18, 2006

February 9, 2007
S&L File No. P25,984 REI
Page 30

In column 51, line 38, the term "3.6" should read -- 3.5 --.

In column 51, line 40, a space should appear in place of the comma in the phrase "mmoles),in" so that the phrase reads -- mmoles), in --.

In column 51, line 40, a space should appear in the term "(25ml)" so that the term reads -- (25 ml) --.

In column 51, line 41, a space should appear in the term "(75ml)" so that the term reads -- (75 ml) --.

In column 51, line 41, the term "and" should read -- end --.

In column 51, line 46, a space should appear in the term "80g," so that the term reads -- 80 g, --.

In column 51, line 53, a hyphen should appear in the term "2methylphenyl" so that the term reads -- 2-methylphenyl --.

In column 51, lines 55 to 56, between the line consisting of "113°–114° C." and line beginning with the term "Calculated", a line consisting of the phrase -- ANALYSIS: -- should appear.

In column 51, line 56, the formula "$C_{24}H_{27}FN_2O3$:" should read -- $C_{24}H_{27}FN_2O_3$: --

In column 51, line 64, the extra hyphen should not appear in the fragment

"(-4-piperidinyl)" so that the fragment reads -- (4-piperidinyl) --.

In column 51, line 66, the term "(2.5)," should read -- (2.5 g), --.

In column 51, line 67, a comma should appear in place of the period in the phrase "3.74 g.", so that the phrase reads -- 3.74 g, --.

In column 52, line 1, a space should appear in the term "6hr." so that the term reads -- 6 hr. --.

In column 52, line 5, a comma should appear after the term "(MgSO$_4$)" so that the term reads -- (MgSO$_4$), --.

In column 52, line 20, an open bracket symbol should appear in place of the closed bracket symbol, and a hyphen should appear, in the fragment "]4(6-" so that the fragment reads -- [4-(6- --.

In column 52, line 24, a hyphen should appear in place of the space in the fragment "fluoro 3-" so that the fragment reads -- fluoro-3- --.

In column 52, line 25, the phrase "15.4 moles" should read -- 15.4 mmoles --.

In column 52, line 41, a hyphen should appear in the term "4methoxyphenyl" so that the term reads -- 4-methoxyphenyl --.

In column 52, line 44, a centerdot should appear in place of the period between the fragments "O$_4$" and "0.5" so that the fragments reads -- O$_4$·0.5 --.

SYNNESTVEDT & LECHNER LLP
U.S. Pat. No. RE39,198
Issued July 18, 2006

February 9, 2007
S&L File No. P25,984 REI
Page 32

In column 52, line 49, a closed parenthesis symbol should appear in place of the closed bracket symbol in the fragment "(1-piperazinyl]" so that the fragment reads -- (1-piperazinyl) --.

In column 52, line 51, the extra hyphen should not appear in the fragment "(-6-chloro" so that the fragment reads -- (6-chloro --.

In column 52, line 52, the fragment "phenylsulphonyl" should read -- phenylsulfonyl --.

In column 52, line 54, a space should appear after the phrase "LiAlH$_4$(958" so that the phrase reads -- LiAlH$_4$ (958 --.

In column 52, line 55, a close parenthesis symbol should appear in the phrase "0.958 mol." so that the phrase reads -- 0.958 mol). --.

In column 52, line 57, a space should appear in the term "4hours" so that the term reads -- 4 hours --.

In column 52, line 64, the term "1531.0 g" should read -- 151.0 g --.

In column 53, line 2, a period should appear in the phrase "21 g" so that the phrase reads -- 2.1 g --.

In column 53, line 13, the extra hyphen should not appear in the fragment "piperidinyl]-propoxy" so that the fragment reads -- piperidinyl]propoxy --.

FEB 2 0 2007

SYNNESTVEDT & LECHNER LLP
U.S. Pat. No. RE39,198
Issued July 18, 2006

February 9, 2007
S&L File No. P25,984 REI
Page 33

In column 53, line 14, the extra hyphen should not appear in the fragment "(-4" so that the fragment reads -- (4 --.

In column 53, line 15, a comma should appear after the phrase "0.016 mol)" so that the phrase reads -- 0.016 mol), --.

In column 53, line 15, a comma should appear after the phrase "(2.2 g)" so that the phrase reads -- (2.2 g), --.

In column 53, line 26, the fragment "O3" should read -- O_3 --.

In column 53, line 32, a comma should appear in place of the period in the fragment "1.2" so that the fragment reads "1,2"

In column 53, line 33, a closed bracket symbol should appear after the fragment "propoxy" so that the fragment reads -- propoxy] --.

In column 53, line 38, after the term "(3.0 g)," the term -- and -- should appear.

In column 53, line 38, the term "(20 ml)" should read -- (20 ml) and --.

In column 53, line 44, a comma should appear after the term "brine" so that the term reads -- brine, --.

In column 53, line 47, the term "in ethane" should read -- in dichloromethane --.

In column 53, line 54, a period should appear in place of a comma in the term "m.p," so that the term reads -- m.p. --.

In column 53, line 65, the term "CO_3(3 g)" should read -- CO_3 (3 g) --.

In column 54, line 5, the term "methane" should be deleted.

In column 54, line 6, a comma should be inserted after the term "48%" so that the term reads -- 48%, --.

In column 54, line 7, a hyphen should appear in the fragment "2benzisoxazol" so that the fragment reads -- 2-benzisoxazol --.

In column 54, line 14, a hyphen should appear in the fragment "4(6" so that the fragment reads -- 4-(6 --.

In column 54, line 14, the fragment "piperidinyl" should read -- piperazinyl --.

In column 54, line 17, an extra hyphen should not appear in the fragment "(-1-piperazinyl)" so that the fragment reads -- (1-piperazinyl) --.

In column 54, line 21, the term "Alter" should read -- After --.

In column 54, line 27, a space should appear in the term "2days" so that the term reads -- 2 days --.

In column 54, line 29, a space should appear in the term "2silica" so that the term

reads -- 2 silica --.

In column 54, line 33, a closed bracket symbol should appear in place of a closed
parenthesis symbol in the fragment "propoxy)" so that the fragment reads
-- propoxy] --.

In column 54, line 40, a closed parenthesis symbol should appear in the fragment
"3-yl" so that the fragment reads -- 3-yl) --.

In column 54, line 43, a comma should appear in place of period in the fragment "1.2"
so that the fragment reads -- 1,2 --.

In column 54, line 45, the phrase "(6.0 g 0.0218 mol). KI" should read
-- (6.0 g, 0.0200 mol), K_2CO_3 (3.0 g, 0.0218 mol), KI --.

In column 54, line 46, a space should appear in the term "5hours" so that the term
reads -- 5 hours --.

In column 54, line 52, a space should appear in the term "2silica" so that the term
reads -- 2 silica --.

In column 54, line 53, the term "an" should read -- as --.

In column 54, line 56, a hyphen and a closed bracket symbol should appear in the
fragment "-3methoxyphenyl" so that the fragment reads
-- -3-methoxyphenyl] --.

SYNNESTVEDT & LECHNER LLP
U.S. Pat. No. RE39,198
Issued July 18, 2006

February 9, 2007
S&L File No. P25,984 REI
Page 36

In column 54, line 59, the term "9.36%" should read -- 9.56% --.

In column 54, line 63, the hyphen should not appear in the fragment "(-6" so that the fragment reads -- (6 --..

In column 54, line 64, the hyphen should not appear in the fragment "-propoxyl" so that the fragment reads -- propoxyl --.

In column 54, line 67, a comma and a space should appear in place of the hyphen in the term "g)-4-" so that the fragment reads -- g), 4- --.

In column 55, line 2, the term "is" should read -- in --.

In column 55, line 2, a space should appear in the term "(70ml)" so that the term reads -- (70 ml) --.

In column 55, line 2, the term "reflex" should read -- reflux --.

In column 55, line 2, a space should appear in the term "3hr." so that the term reads -- 3 hr. --.

In column 55, line 3, the term "wet" should read -- was --.

In column 55, line 5, the term "(50 ml)" should read -- (250 ml) --.

In column 55, line 11, a space should appear in the term "(25ml) so that the term reads -- (25 ml) --.

In column 55, line 11, the term "3.8 m" should read -- 3.8 gm --.

In column 55, line 11, the hyphen should not appear in the fragment "(-6" so that the fragment reads -- (6 --.

In column 55, line 20, the hyphen in the fragment "]-butoxy" should be deleted.

In column 55, line 24, an open parenthesis should appear in the phrase "2.6 g," so that the phrase reads -- (2.6 g, --.

In column 55, line 29, a closed bracket symbol should appear in the term "butoxy" so that the term reads -- butoxy] --.

In column 55, line 32, the term "$C_{23}H_{25}FN_2O_3$" should read -- $C_{25}H_{30}FN_3O_3$ --.

In column 55, line 38, the term "piperizinyl" should read -- piperazinyl --.

In column 55, line 42, the term "0.0073 mol" should read -- 0.0075 mol --.

In column 55, line 42, a space should appear in the term "(15ml)" so that the term reads -- (15 ml) --.

In column 55, line 44, a hyphen should appear in the phrase "off white" so that the phrase reads -- off-white --.

In column 55, line 51, a space should appear in the term "4days" so that the term reads

SYNNESTVEDT & LECHNER LLP
U.S. Pat. No. RE39,198
Issued July 18, 2006

February 9, 2007
S&L File No. P25,984 REI
Page 38

-- 4 days --.

In column 55, line 55, a hyphen should appear in the fragment "[4("so that the
fragment reads -- [4-(--.

In column 55, line 56, the hyphen in the fragment "-propoxy" should be deleted so that
the fragment reads -- propoxy --.

In column 55, line 59, a centerdot should appear in place of the period in the fragment
"$O_4.1$" so that the fragment reads -- $O_4 \cdot 1$ --.

In column 56, line 27, the fragment "benziothiazole" should read -- benzisothiazole --.

In column 56, line 46, the fragment "1-piperazinyl" should read -- 1,2-piperazinyl --.

In column 56, line 50, a centerdot should appear in place of the period in the fragment
"S.0" so that the fragment reads -- $S \cdot 0$ --.

In column 56, line 57, the fragment "propoxyphenyl" should read
-- propoxy]phenyl --.

In column 56, line 59, the term "(1.3)" should read -- (1.3 g)--.

In column 57, line 4, the fragment "benzoisoxazol" should read -- benzisoxazol --.

In column 57, line 4, a closed bracket symbol should appear in place of the closed
parenthesis symbol in the fragment "piperidinyl)" so that the fragment reads

-- piperidinyl] --.

In column 57, line 8, a colon should appear in place of the semicolon in the formula
    fragment "O_3;" so that the fragment reads -- O_3: --.

In column 57, line 10, two spaces should appear in the term "C4.11%" so that the term
    reads -- C 4.11% --.

In column 57, line 21 to 22, the phrase "0.0072 mol" should read -- 0.0072 mmol --.

In column 57, line 34, the fragment "benzoisothiazol" should read
    -- benzisothiazol --.

In column 57, line 40, a period should appear in place of the degree sign and the dash
    in the phrase "10° − 12%" so that the phrase reads -- 10.12% --.

In column 57, line 47, the fragment "benzoisoxazole" should read -- benzisoxazole --.

In column 57, line 66, a closed bracket should appear in the fragment
    "[3-(1-piperazinyl)" so that the fragment reads -- [3-(1-piperazinyl)] --.

In column 57, line 67, the term "$K_{2\ CO3}$" should read -- K_2CO_3 --.

In column 58, line 23, the term "methoxyhenyl" should read -- methoxyphenyl --.

In column 58, line 29, the term "(0.1)" should read -- (0.1 g) --.

FEB 20 2007

In column 58, line 48, the character "8" should read -- [--.

In column 60, line 32, the fragment "methyoxyphenyl" should read
        -- methoxyphenyl --.

In column 60, line 56, the term "(3.0)," should read -- (3.0 g) --.

In column 61, line 32, the term "benzisoxaol" should read -- benzisoxazol --.

In column 61, line 48, a hyphen should appear in the fragment "2benzisoxazole" so
        that the fragment reads -- 2-benzisoxazole --.

In column 62, line 11, the term "(3.22)" should read -- (3.22 g) --.

In column 62, line 53, the term "(3)" should read -- (3 g) --.

In column 62, line 59, the term "(6.4)" should read -- (6.4 g) --.

In column 63, line 18, the term "eluent" should read -- eluted --.

In column 63, line 39, the term "KI(0.10)," should read -- KI (0.10 g) --.

In column 63, line 47, the term "column" should read -- columns --.

In column 64, line 26, the term "K_2COO_3" should read -- K_2CO_3 --.

In column 64, line 33, the term "columns" should read -- column --.

FEB 2 0 2007

In column 64, line 46, the term "(12.5)" should read -- (12.5 g) --.

In column 64, line 53, the term "columns" should read -- column --.

In column 64, line 60, the term "4.88%" should read -- 4.48% --.

In column 65, line 1, the term ")400 ml)" should read -- (400 ml) --.

In column 65, line 10, the term "weighted" should read -- weighed --.

In column 65, line 41, the fragment "benzoisoxazol" should read -- benzisoxazol --.

In column 65, line 44, the fragment "propxoy" should read --propoxy --.

In column 65, line 48, a period should appear in place of the comma in the number
        "0,036" so that the number reads -- 0.036 --.

In column 66, line 45, the character ">" should read --] --.

In column 67, line 6, the fragment "piperidinyl)" should read -- piperidinyl] --.

In column 67, line 14, the fragment "1,3-benzisoxazol" should read
        -- 1,2-benzisoxazol --.

In column 67, line 64, the term "9.3." should read -- 9.3 g. --.

In column 68, line 42, the term "(2.4)" should read -- (2.4 g) --.

In column 69, line 14, the number "0.053" should read -- 0.0053 --.

In column 69, line 29, the fragment "methylenebenzene" should read
    -- methylbenzene --.

In column 70, line 10, a closed bracket symbol should appear in place of the closed
    parenthesis symbol in the fragment "piperidinyl)" so that the fragment reads
    -- piperidinyl] --.

In column 70, line 13, in two occurrences, periods should appear in place of commas
    in the terms "0,022 mol" so that the terms read -- 0.022 mol --.

In column 70, line 26, a closed bracket symbol should appear in place of closed
    parenthesis symbol in the fragment "piperidinyl)" so that the fragment reads
    -- piperidinyl] --.

In column 70, line 32, the term "9.53%" should read -- 9.35% --.

In column 70, line 42, the term "(5.7)," should read -- (5.7 g), --.

In column 70, line 43, a period should appear in place of a comma in the phrase
    "0,056 mol" so that the phrase reads -- 0.056 mol --.

In column 70, line 64, a hyphen should appear in the fragment "3chloropropoxy" so
    that the fragment reads -- 3-chloropropoxy --.

FEB 2 0 2007

2 0 2007

In column 70, line 65, a space should appear in the term "CO_3(2.8 g)" so that the term reads -- CO_3 (2.8 g) --.

In column 71, line 2, a space should appear in the term "afford9.5" so that the term reads -- afford 9.5 --

In column 71, line 37, the fragment "phenyl" should read -- phenol --.

In column 71, line 54, the term "(0.4)," should read -- (0.4 g), --.

In column 71, line 54, the term "(2.5)," should read -- (2.5 g), --.

In column 72, line 1, the fragment "propyl-]4" should read -- propyl]-4 --.

In column 72, line 29, the term "liquid" should read -- light --.

In column 72, line 42, the term "(~ 10)" should read -- (~ 10 g) --.

In column 72, line 55, a hyphen should appear in the term "2benzisoxazol" so that the term reads -- 2-benzisoxazol --.

In column 73, line 6, the term "42 moles" should read -- 42 mmoles --.

In column 73, line 6, the term "58 moles" should read -- 58 mmoles --.

In column 73, line 12, the term "(^{18} 18 g)" should read -- (~ 18 g) --.

In column 74, line 7, the fragment "1-[3-[4-(6" should read -- 1-[4-[3-[4-(6 --.

In column 74, line 31, a closed parenthesis symbol should appear in place of closed
    bracket symbol in the fragment "phenyl]ethanone" so that the fragment reads
    -- phenyl)ethanone --.

In column 74, line 33, an open bracket symbol should appear in place of the first open
    parenthesis symbol in the fragment "1-((3-" so that the fragment reads
    -- 1-[(3- --.

In column 75, line 11, the fragment "C_{16}" should be deleted.

In column 75, line 30, the term "fumaric" should read -- fumarate --.

In column 75, line 34, the term "m.p.=98° " should read -- m.p.= 198° --.

In column 75, line 64, the term "Recrystallized" should read -- Recrystallization --.

In column 76, line 1, a colon should appear in place of the semicolon, and a symbol
    "O" should appear, in the fragment "N_3; " so that the fragment reads -- NO_3: --.

In column 76, line 8, a period should appear in place of the comma in the term "0,017"
    so that the term reads -- 0.017 --.

In column 76, line 21, the fragment "benzoisothiazol" should read
    -- benzisothiazol --.

In column 76, line 44, the term "triburation" should read -- trituration --.

In column 76, line 61, the fragment "benzoisoxazol" should read -- benzisoxazol --.

In column 77, line 12, the fragment "benzoisoxazole" should read -- benzisoxazole --.

In column 77, line 19, the phrase "weighted 7 ." should read -- weighed 7 g. --.

In column 77, line 31, the fragment "benzoisoxazol" should read -- benzisoxazol --.

In column 77, line 35, the fragment "benzoisoxazol" should read -- benzisoxazol --.

In column 77, line 36, a hyphen should appear in the fragment "3yl" so that the
        fragment reads -- 3-yl --.

In column 77, line 42, the term "whether" should read -- white --.

In column 78, line 1, the term "(75 mg)" should read -- (75 ml) --.

In column 78, line 39, two spaces should appear in the term "H12.55%" so that the
        term reads -- H 12.55% --.

In column 78, line 43, the character "]" in the fragment "Fluoro]" should be deleted so
        that the fragment reads -- Fluoro --.

In column 78, line 48, the term "to" should read -- in --.

FEB 2 0 2007

Synnestvedt & Lechner LLP
U.S. Pat. No. RE39,198
Issued July 18, 2006

February 9, 2007
S&L File No. P25,984 REI
Page 46

In column 78, line 50, the term "wa" should read -- was --.

In column 78, line 59, the term "mixtures" should read -- minutes --.

In column 79, line 20, a closed bracket symbol should appear in the fragment "oxy-"
so that the fragment reads -- oxy]- --.

In column 79, line 28, the term "200" should read -- 20 --.

In column 79, line 62, a space should appear in the fragment "CO$_3$(" so that the
fragment reads -- CO$_3$ (--.

In column 80, line 26, the term "(3>250ml)." should read -- (3×250ml). --.

In column 80, line 67, the term "form" should read -- from --.

In column 81, line 4, a hyphen should appear in the fragment "4benzyloxyphenyl" so
that the fragment reads -- 4-benzyloxyphenyl --.

In column 81, line 14, a closed parenthesis symbol should appear in place of closed
bracket symbol in the term "(3-Chloropropoxy]" so that the term reads
-- (3-Chloropropoxy) --.

In column 81, line 45, the fragment "chloropropxy" should read -- chloropropoxy --.

In column 81, line 63, the fragment "phenyl" should read -- propyl --.

FEB 2 0 2007

In column 82, line 27, the phrase "of white" should read -- of a white --.

In column 82, line 32, the term "fumaric" should read -- fumarate --.

In column 82, line 34, the fragment "-3-[3-" should read -- -3-[1-[3- --.

In column 82, line 41, the phrase "9.39% H" should read -- 9.39% N --.

In column 82, line 47, a period should appear in place of a comma in the term "0,046"
    so that the term reads -- 0.046 --.

In column 83, line 44, the fragment "methylchloride" should read -- mesylchloride --.

In column 83, line 51, the fragment "methoxymethyl" should read
    -- mesyloxymethyl --.

In column 84, line 33, the term "hydroxymethyl" should read -- hydroxyethyl --.

In column 87, line 62, the term "4.48." should read -- 4.48 g. --.

In column 87, line 65, the term "2.0" should read -- 2.0 g --.

In column 89, line 26, the term "10.7 mole" should read -- 10.7 mmole --.

In column 89, line 27, the term "10 moles" should read -- 10 mmoles --.

In column 89, line 67, the term "94 moles" should read -- 94 mmoles --.

In column 90, line 4, no period should appear in the phrase "4.2 g" so that the phrase reads -- 42 g --.

In column 90, line 17, a closed parenthesis symbol should appear in place of the closed bracket symbol in the fragment "yl]butyl" so that the fragment reads -- yl)butyl --.

In column 90, line 42, the term "perchloroate" should read -- perchlorate --.

In column 90, line 66, the comma after the term "dispersion)" should be deleted.

In column 91, line 2, a hyphen should appear in the term "3hydroxyphenyl" so that the term reads -- 3-hydroxyphenyl --.

In column 91, line 52, an open parenthesis symbol should appear in the fragment "1-phenylmethyl)" so that the fragment reads -- 1-(phenylmethyl) --.

In column 92, line 1, a centerdot should appear in place of the period in the formula "$NH_2OH.HCl$" so that the formula reads -- $NH_2OH \cdot HCl$ --.

In column 92, line 44, the term "59 moles" should read -- 59 mmoles --.

In column 93, line 18, the term "hydrochloride" should read -- hydrochloric --.

In column 94, line 55, the term "3.5 m" should read -- 3.5 gm --.

FEB 2 0 2007

In column 95, line 29, two periods and two commas should appear in the phrase
   "(5 15 gm 23 4 mmol)" so that the phrase reads -- (5.15 gm, 23.4 mmol), --.

In column 95, line 67, the term "72 m" should read -- 72 gm --.

In column 96, line 28, the term "~ ^{10} gm" should read -- ~ 10 gm --.

In column 96, line 52, the term "30 in" should read -- 30 gm --.

In column 97, line 54, the term "1.36 in" should read -- 1.36 gm --.

In column 98, line 32, the term "600" should read -- 660 --.

In column 98, line 34, the phrase "1 43 in," should read -- 1.43 gm --.

In column 98, line 55, the term "660 gm," should read -- 660 mg, --.

In column 99, line 1, the term "860" should read -- 850 --.

In column 100, line 52, the term beginning with "N-"should begin with
   -- Methyl N- --.

In column 101, line 12, a hyphen should appear in the fragment "-3yl" so that the
   fragment reads -- -3-yl --.

In column 101, line 40, the term "8.83 in" should read -- 8.83 gm --.

FEB 2 0 2007

In column 101, line 66, the term "3.1 in" should read -- 3.1 gm --.

In column 102, line 16, the phrase "the acetonitrile" should read
        -- and acetonitrile --.

In column 102, line 44, no period should appear in the phrase "1.50 gm" so that the
        phrase reads -- 150 gm --.

In column 102, line 66, the term "allowed" should read -- showed --.

In column 103, line 25, the term "H_{20}" should read -- H_2O --.

In column 104, line 10, a period should appear in place of the hyphen in the phrase
        "0-66 g" so that the phrase reads -- 0.66 g --.

In column 105, line 4, the term "being" should read -- beige --.

In column 106, line 37, an additional hyphen should appear in the fragment
        "-2methyl-" so that the fragment reads -- -2-methyl- --.

In column 106, line 42, the phrase "24.9 moles" should read -- 24.9 mmoles --.

In column 106, line 43, the phrase "26.5 moles" should read -- 26.5 mmoles --.

In column 106, line 55, a centerdot should appear in place of a period in the fragment
        "$O_4.C_4$" so that the fragment reads -- $O_4{\cdot}C_4$ --.

In column 108, lines 7 to 8, the em dash should not appear in the term

"MeOH-CH—$_2$Cl$_2$ "so that the term reads -- MeOH-CH$_2$Cl$_2$ --

In column 108, line 47, the term "0.0025 mole" should read -- 0.025 mole --.

In column 110, line 57, the term "with" should read -- white --.

In column 110, line 59, a centerdot should appear in place of a period in the fragment

"O$_2$.C$_4$" so that the fragment reads -- O$_4$·C$_4$ --.

In column 110, line 66, the fragment "benzisoxaxol" should read -- benzisoxazol --.

In column 111, line 6, the term "7.27 gum" should read -- 7.27 gm --.

In Claim 1, column 111, line 57, the term "pheny" should read --phenyl--.

In Claim 1, column 111, line 60, the semicolon should appear after the chemical

structure and not as a part of the structure so that the structure

lower alkyleneyl———〈 〉—(Z$_1$)$_p$;

reads as

lower alkyleneyl———〈 〉—(Z$_1$)$_p$;

In Claim 1, column 112, lines 5 to 8, the hyphens in the formulas should be em dashes
to signify single bonds, so that the phrase

"–C(=O)-alkyl, –C(=O)–O-alkyl, –C(=O)-aryl, –C(=O)-heteroaryl,

[–CH(OR⁷)-alkyl, –C(=W)-alkyl, –C(=W)-aryl, and –C(=W)-heteroaryl;]

or –CH(OR₇)-alkyl" reads as

-- –C(=O)–alkyl, –C(=O)–O–alkyl, –C(=O)–aryl, –C(=O)–heteroaryl,

[–CH(OR⁷)–alkyl, –C(=W)–alkyl, –C(=W)–aryl, and –C(=W)–heteroaryl;]

or –CH(OR₇)–alkyl --.

In Claim 1, column 112, line 14, the semicolon should appear after the chemical
structure and not as a part of the structure so that the structure

  reads as

In Claim 1, column 112, line 35, the symbol "O" should appear, and the hyphens in the
formulas should be em dashes to signify single bonds, in the phrase

"–C(=)-aryl or –C(=O)-heteroaryl," so that the phrase reads

-- –C(=O)–aryl or –C(=O)–heteroaryl, --.

In Claim 7, column 112, line 61, a closed bracket symbol should appear immediately
after the fragment "ethoxy" so that the fragment reads -- ethoxy] --.

In Claim 12, column 113, line 13, the phrase "as claim" should read -- in claim --.

In Claim 12, column 113, line 14, the fragment "piperindyl" should read

-- piperidinyl --.

In Claim 17, column 113, line 34, the fragment "benzisoxzol" should read
-- benzisoxazol --.

In Claim 18, column 113, line 39, the fragment "propoxyl" should read -- propoxy --.

In Claim 21, column 113, line 49, an open bracket symbol should appear in place of
the open parenthesis symbol in the fragment "1-(4-[3-" so that the fragment
reads -- 1-[4-[3- --.

In Claim 23, column 113, line 58, the duplicate "1,2-" should not appear in the
fragment "fluoro-1,2-1,2-benzisoxazol" so that the fragment reads
-- fluoro-1,2-benzisoxazol --.

In Claim 29, column 114, line 15, the fragment "[4-ethoxyethyl)" should read
-- [4-(1-ethoxyethyl) --.

In Claim 32, column 114, line 27, the hyphen in front of "propoxy" should be deleted,
so that the fragment "piperidinyl]-propoxy" reads -- piperidinyl]propoxy --.

In Claim 35, column 114, line 38, the hyphen in front of "propoxy" should be deleted,
so that the fragment "piperidinyl]-propoxy" reads -- piperidinyl]propoxy --.

In Claim 41, column 114, line 61, the hyphen in front of "propoxy" should be deleted,
so that the fragment "piperidinyl]-propoxy" reads -- piperidinyl]propoxy --.

FEB 2 0 2007

In Claim 42, column 114, line 65, the hyphen in front of "propoxy" should be deleted, so that the fragment "piperidinyl]-propoxy" reads -- piperidinyl]propoxy --.

In Claim 46, column 115, line 13, the fragment "benzisoxaxol" should read -- benzisoxazol --.

In Claim 53, column 115, line 41, an additional hyphen should appear in the fragment "-[4(6-" so that the fragment reads -- -[4-(6- --.

In Claim 53, column 115, line 42, the fragment "3-(methylamino)phenyl" should read -- 3-methoxyphenyl --.

In Claim 57, column 115, line 58, a hyphen should appear in the fragment "2butenyl" so that the fragment reads -- 2-butenyl --.

In Claim 59, column 115, line 66, a hyphen should appear the fragment "2butenyl" so that the fragment reads -- 2-butenyl --.

In Claim 60, column 116, line 2, the fragment "Fluoro" should read -- fluoro --.

In Claim 63, column 116, line 15, the fragment "benzisothazol" should read -- benzisothiazol --.

In Claim 64, column 116, line 19, the hyphen in front of "propoxy" should be deleted, so that the fragment "piperidinyl]-propoxy" reads -- piperidinyl]propoxy --.

In Claim 67, column 116, line 38, the term "slats" should read -- salts --.

FEB 2 0 2007

SYNNESTVEDT & LECHNER LLP
U.S. Pat. No. RE39,198
Issued July 18, 2006

February 9, 2007
S&L File No. P25,984 REI
Page 55

In the deleted Claim 76, in column 116, lines 61 to 62, the formula

"–CH_2–CH=CH–CH_2– " should read -- –CH_2–CH=CH=CH_2– --.

In Claim 77, column 116, line 65, a space should appear in the term "C_1-C_3alkoxy" so that the term reads -- C_1-C_3 alkoxy --.

In Claim 77, column 116, line 67, the hyphen in the formula should be em dashes to signify single bonds, so that the term "–C(=O)-lower alkyl" reads as -- –C(=O)–lower alkyl --.

In Claim 78, column 117, line 14, the phrase "alkoxy, [hydroxy, " should read -- alkoxy[, hydroxy, --

In Claim 78, column 117, entire lines 16 to 25, that is, all text beginning with the first occurrence of "R is hydrogen" and ending with the first occurrence of "m is 1, 2, or 3;", are to be deleted.

In Claim 78, column 117, line 29, the hyphen in the formula should be an em dash to signify single bond, so that the term "–CH(OR$_7$)-alkyl" reads as -- –CH(OR$_7$)–alkyl --.

In Claim 78, column 117, line 31, the hyphen in the formula should be an em dash to signify a single bond, so that the phrase "lower alkyl-C(=O)–" reads -- lower alkyl–C(=O)– --.

In Claim 79, column 117, line 53, the phrase "alkoxy, [hydroxy," should read

-- alkoxy[, hydroxy, --

In Claim 79, column 117, line 58, the hyphen in the first formula should be an em dash
to signify a single bond, so that the phrase "alkyl-C(=O)–" reads
-- alkyl–C(=O)– --.

In Claim 79, column 117, lines 58 to 59, the hyphen in the third formula should be an
em dash to signify a single bond, so that the phrase "–CH(OR_7)-alkyl;" reads
-- –CH(OR_7)–alkyl; --.

In Claim 79, column 117, line 63, a comma should appear after the term "hydrogen",
so that the phrase "hydrogen lower" reads -- hydrogen, lower --.

In Claim 80, column 118, line 20, a semicolon should appear in place of the comma at
the end of the line, so that the phrase "–O–," reads -- –O–; --.

In Claim 80, column 118, line 22, the term "R_{20} " should read
-- R_{20} is –$(CH_2)_n$– where n is 2, 3, 4 or 5; --.

In Claim 80, column 118, line 28, the formula " –CH_2–CH≡C–CH_2–CH_2– " should
read -- –CH_2–C≡C–CH_2–CH_2– --.

In Claim 80, column 118, line 31, the phrase "R_{22} is R_{20} is R_{21} " should read
-- R_{22} is R_{20} or R_{21} --

In Claim 80, column 118, line 37, the semicolon should appear after the chemical
structure and not as a part of the structure so that the structure

lower alkyleneyl—⬡(Z₁)ₚ;

reads as

lower alkyleneyl—⬡(Z₁)ₚ ;

In Claim 80, column 118, line 40, the term "wherein" should read -- where --.

In Claim 80, column 118, line 60, the semicolon should appear after the chemical

structure and not as a part of the structure so that the structure

—⬡R₅;   reads as   —⬡R₅ ;

In Claim 80, column 119, line 18, the hyphen in the formulas should be em dashes to

signify single bonds, so that the phrase

"–C(=O)-heteroaryl or –C(=W)-heteroaryl;" reads

-- –C(=O)–heteroaryl or –C(=W)–heteroaryl; --.

In Claim 87, column 120, lines 9 to 11, the hyphens in the formulas should be em

dashes to signify single bonds, so that the phrase

"–C(=O)-alkyl, –C(=O)–O-alkyl, –C(=O)-aryl, –C(=O)-heteroaryl,

–CH(OR₇)-alkyl, –C(=W)-alkyl, –C(=W)-aryl, and –C(=W)-heteroaryl;" reads

-- –C(=O)–alkyl, –C(=O)–O–alkyl, –C(=O)–aryl, –C(=O)–heteroaryl,

–CH(OR₇)–alkyl, –C(=W)–alkyl, –C(=W)–aryl, and –C(=W)–heteroaryl; -- .

In Claim 87, column 120, line 17, the semicolon should appear after the chemical structure and not as a part of the structure so that the structure

reads as

In Claim 87, column 120, line 21, the subscript "three" should be a "five" so that the term " R_3 " reads -- R_5 --.

In Claim 87, column 120, line 38, a comma should appear after the term "aryl", so that the phrase "C_1-C_3 acyl aryl " reads -- C_1-C_3 acyl, aryl --.

In Claim 87, column 120, line 39, the hyphens in the formulas should be em dashes to signify single bonds, so that the phrase

"–$C(=O)$-aryl, –$C(=O)$-heteroaryl," reads

-- –$C(=O)$–aryl, –$C(=O)$–heteroaryl, --.

In Claim 89, column 120, line 53, a comma should appear after the first term "acid", so that the phrase "acid acetic acid," reads -- acid, acetic acid, --.

In Claim 95, column 120, line 67, no comma should appear after the term "hydroxy", so that the phrase "hydroxy, and" reads -- hydroxy and --.

In Claim 97, column 121, line 3, the subscript "seven" should be a "one" so that the term the term "R_7" reads --R_1 --.

In Claim 98, column 121, line 7, the subscript "two" should be a "three" so that the term " $-COCF_2$ " reads -- $-COCF_3$ --.

In Claim 98, column 121, line 8, the subscript "two" should be a "three" so that the term " $-OCF_2$ " reads -- $-OCF_3$ --.

In Claim 98, column 121, line 8, the term "*and alkylamino,*" should read -- *and* --.

In Claim 98, column 121, line 12, the comma at the end of the claim should be a period.

In Claim 100, column 121, line 18, the term "compond" should read --compound--.

In Claim 104, column 121, line 47, no comma should appear in the term "hydroxy," so that the term reads -- hydroxy --.

In Claim 104, column 121, line 54, the semicolon should appear after the chemical structure and not as a part of the structure so that the structure

$$\text{lower alkyleneyl} - \left\langle \bigcirc \right\rangle (Z_1)_p;$$

reads

$$\text{lower alkyleneyl} - \left\langle \bigcirc \right\rangle (Z_1)_p \quad ;$$

In Claim 104, column 121, line 59, the term "*halogen.*" should be replaced with

Synnestvedt & Lechner llp
U.S. Pat. No. RE39,198
Issued July 18, 2006

February 9, 2007
S&L File No. P25,984 REI
Page 60

-- halogen;

R_{20} *is* $-(CH_2)_n-$, *wherein n is 2, 3, 4 or 5;*

R_{21} *is*

$-CH_2-CH=CH-CH_2-$,

$-CH_2-C\equiv C-CH_2-$,

$-CH_2-CH=CH-CH_2-CH_2-$,

$-CH_2-CH_2-CH=CH-CH_2-$,

$-CH_2-C\equiv C-CH_2-CH_2-$, *or*

$-CH_2-CH_2-C\equiv C-CH_2-$,

the $-CH=CH-$ bond being cis or trans;

R is hydrogen, lower alkyl, lower alkoxy, hydroxyl, carboxyl, chlorine, fluorine,

bromine, iodine, amino, lower mono or dialkylamino, nitro, lower alkyl thio,

trifluoromethoxy, cyano, acylamino, trifluoromethyl, trifluoroacetyl,

aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, formyl,

$-C(=O)-alkyl$, $-C(=O)-O-alkyl$, $-C(=O)-aryl$, $-C(=O)-heteroaryl$,

$-CH(OR_7)-alkyl$, $-C(=W)-alkyl$, $-C(=W)-aryl$, *or* $-C(=W)-heteroaryl;*

wherein alkyl is lower alkyl; aryl is phenyl or

wherein R_5 is hydrogen, lower alkyl, lower alkoxy, hydroxy, chlorine, fluorine,

bromine, iodine, lower monoalkylamino, lower dialkylamino, nitro, cyano,

trifluoromethyl, or trifluoromethoxy;

heteroaryl is

SYNNESTVEDT & LECHNER LLP
U.S. Pat. No. RE39,198
Issued July 18, 2006

February 9, 2007
S&L File No. P25,984 REI
Page 61

;

wherein Q$_3$ is –O–, –S–, –NH–, or –CH=N–;

W is CH$_2$ or CHR$_8$ or N–R$_9$;

*R$_7$ is hydrogen, lower alkyl, or acyl;*

R$_8$ is lower alkyl;

R$_9$ is hydroxy, lower alkoxy, or –NHR$_{10}$; and

R$_{10}$ is hydrogen, lower alkyl, C$_1$-C$_3$ acyl, aryl, –C(=O)–aryl, or –C(=O)–heteroaryl,

wherein aryl and heteroaryl are as defined above; and m is 1, 2, or 3;

all geometric, optical and stereoisomers thereof, or a pharmaceutically acceptable

acid addition salt thereof. --.

In Claim 114, column 122, line 25, the hyphen in the last formula should be symbol

for a single bond, so that the formula

reads as

.

In Claim 115, column 122, line 28, the phrase "*and pharmaceutically*" should read

-- *and a pharmaceutically* --.

In Claim 116, column 122, line 30, the phrase "*A antipsychotic*" should read

-- *An antipsychotic* --.

In Claim 120, column 122, lines 45 to 46, the hyphens in the formulas should be em

dashes to signify single bonds, so that the phrase

"*–C(=O)-aryl, –C(=O)-heteroaryl,*" reads

-- –C(=O)–aryl, –C(=O)–heteroaryl, --.

In Claim 121, column 122, line 48, the phrase "*A pharmaceutically composition*"

should read -- *A pharmaceutical composition* --.

In Claim 126, column 122, lines 66 to 67, the hyphens in the formulas should be em

dashes to signify single bonds, so that the phrase

"*–C(=O)-aryl, or –C(=O)-heteroaryl,*" reads

-- *–C(=O)–aryl, or –C(=O)–heteroaryl,* --.

In Claim 132, column 123, line 22, the phrase "*A compound of formula*" should read

--*A compound of the formula* --

In Claim 132, column 123, line 41, the term "*chorine*" should be --*chlorine*--.

In Claim 132, column 123, lines 54 to 57, the hyphens in the formulas should be em

dashes to signify single bonds, so that the phrase

"*–C(=O)-alkyl, –C(=O)-O-alkyl, –C(=O)-aryl, –C(=O)-heteroaryl,*

–CH(OR₇)-alkyl, –C(=W)-alkyl, –C(=W)-aryl, and –C(=W)-heteroaryl;" reads

-- *–C(=O)–alkyl, –C(=O)–O–alkyl, –C(=O)–aryl, –C(=O)–heteroaryl,*

–CH(OR₇)–alkyl, –C(=W)–alkyl, –C(=W)–aryl, and –C(=W)–heteroaryl; -- .

In Claim 132, column 123, line 64, the semicolon should appear after the chemical

structure and not as a part of the structure so that the structure

should read

lower alkyleneyl————⬡—(Z₁)p   ;

In Claim 132, column 124, line 19, the hyphens in the formulas should be em dashes

   to signify single bonds, so that the phrase

   "–C(=O)-aryl or –C(=O)-heteroaryl," reads

   -- –C(=O)-aryl or –C(=O)-heteroaryl, --.

In Claim 132, column 124, lines 25 to 26, the hyphens in the formulas should be em

   dashes to signify single bonds, so that the phrase

   "–C(=W)-alkyl, –C(=W)-aryl, and –C(=W)-heteroaryl;" reads

   -- –C(=W)–alkyl, –C(=W)–aryl, and –C(=W)–heteroaryl; -- .

In Claim 134, column 124, lines 37 to 38, the phrase "furmaric acid" should read

--fumaric acid --.

In Claim 141, column 124, line 52, the term "compond" should read --compound--.

In Claim 142, column 124, line 57, the term "Br,I," should read -- Br, I, --.

In Claim 142, column 124, line 61, the hyphen in the last formula should be symbol

   for a single bond, so that the formula

$$
\begin{array}{cc}
O & O \\
\| & \| \\
\text{———C-lower alkyl.} & \text{———C———lower alkyl.}
\end{array}
$$

reads as

In Claim 143, column 124, lines 143 to 144, the phrase "pharmaceutical acceptable

Synnestvedt & Lechner llp
U.S. Pat. No. RE39,198
Issued July 18, 2006

February 9, 2007
S&L File No. P25,984 REI
Page 64

carrier" should read -- *pharmaceutically acceptable carrier* --.

Remarks

The patent owner requests that a corrected patent for U.S. Patent No. RE39,198 be issued under 37 C.F.R. § 1.322(b) in lieu of the issuance of a Certificate of Correction.

Section 1.322(b) of 37 C.F.R. states the following:

> If the nature of the mistake on the part of the Office is such
> that a certificate of correction is deemed inappropriate in
> form, the Director may issue a corrected patent in lieu thereof
> as a more appropriate form for certificate of correction,
> without expense to the patentee.

The patent owner believes that the large number of errors and the substantive nature of the errors in the printed and electronic versions of the patent are such that a Certificate of Correction would be deemed inappropriate form of correcting the patent. The errors include errors that are based on omitted pages from the claims, extra paragraphs of text in claims, and substantive typographical errors. A Certificate of Correction submitted on Form PTO-1050 to amend all of the errors would be considerably longer than the patent itself.

All of the errors identified in the "Listing of Errors", as set forth above, are Patent Office mistakes. The errors in the present reissued patent (reissued July 18, 2006) include errors vis-à-vis the following documents:

(A)   Reply dated September 13, 2004, filed in response to Examiner's Action dated May 12, 2004;

(B)   Reply dated February 10, 2004, filed in response to Examiner's Action dated November 12, 2003;

(C)   Reply dated August 27, 2003, filed in response to Examiner's Action dated May 27, 2003;

(D)   Reply dated February 28, 2003, filed in response to Examiner's Action dated August 30, 2002;

(E)   Reply dated June 13, 2002, filed in response to Examiner's Action dated December 14, 2001;

(F)   the text of Application No. 09/712,129, filed November 15, 2000, which issued as the present reissue patent;

(G)   Certificate of Correction dated May 23, 1995 of the original U.S. Patent No. 5,364,866;

(H)   the text of the aforementioned '866; and

(I)   Application No. 07/969,383, which issued as the original '866 patent.

Corrections of the errors would not constitute new matter or require re-examination.

In view of the foregoing, the patent owner requests respectfully issuance of a corrected patent of Reissue Patent No. RE39,198. The Commissioner is authorized hereby to charge any fees associated with this Petition to Deposit Account No. 19-5425.

Respectfully submitted,

Peter D. Mlynek

Peter D. Mlynek, Ph.D.
Reg. No. 47,802
Synnestvedt & Lechner LLP
1101 Market Street, Suite 2600
Philadelphia, PA 19107-2950
Telephone: 215-923-4466
Facsimile: 215-923-2189

FEB 2 0 2007